TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview
Tol-like receptor (TLR) agonists, as potent adjuvants, have gained attention in vaccine research for their ability to enhance immune responses. This study focuses on their application in improving vaccine efficacy against key viral infections, including hepatitis B virus (HBV), hepatitis C virus (HC...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1249718/full |
| _version_ | 1797384278456139776 |
|---|---|
| author | Mohammad Enamul Hoque Kayesh Michinori Kohara Kyoko Tsukiyama-Kohara |
| author_facet | Mohammad Enamul Hoque Kayesh Michinori Kohara Kyoko Tsukiyama-Kohara |
| author_sort | Mohammad Enamul Hoque Kayesh |
| collection | DOAJ |
| description | Tol-like receptor (TLR) agonists, as potent adjuvants, have gained attention in vaccine research for their ability to enhance immune responses. This study focuses on their application in improving vaccine efficacy against key viral infections, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), SARS-CoV-2, influenza virus, and flaviviruses, including West Nile virus, dengue virus, and chikungunya virus. Vaccines are crucial in preventing microbial infections, including viruses, and adjuvants play a vital role in modulating immune responses. However, there are still many diseases for which effective vaccines are lacking or have limited immune response, posing significant threats to human health. The use of TLR agonists as adjuvants in viral vaccine formulations holds promise in improving vaccine effectiveness. By tailoring adjuvants to specific pathogens, such as HBV, HCV, HIV, SARS-CoV-2, influenza virus, and flavivirus, protective immunity against chronic and emerging infectious disease can be elicited. |
| first_indexed | 2024-03-08T21:33:08Z |
| format | Article |
| id | doaj.art-5f9c522963234bb2831af8cebea24587 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-03-08T21:33:08Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-5f9c522963234bb2831af8cebea245872023-12-21T04:43:57ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2023-12-011410.3389/fmicb.2023.12497181249718TLR agonists as vaccine adjuvants in the prevention of viral infections: an overviewMohammad Enamul Hoque Kayesh0Michinori Kohara1Kyoko Tsukiyama-Kohara2Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal, BangladeshDepartment of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, JapanTransboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, JapanTol-like receptor (TLR) agonists, as potent adjuvants, have gained attention in vaccine research for their ability to enhance immune responses. This study focuses on their application in improving vaccine efficacy against key viral infections, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), SARS-CoV-2, influenza virus, and flaviviruses, including West Nile virus, dengue virus, and chikungunya virus. Vaccines are crucial in preventing microbial infections, including viruses, and adjuvants play a vital role in modulating immune responses. However, there are still many diseases for which effective vaccines are lacking or have limited immune response, posing significant threats to human health. The use of TLR agonists as adjuvants in viral vaccine formulations holds promise in improving vaccine effectiveness. By tailoring adjuvants to specific pathogens, such as HBV, HCV, HIV, SARS-CoV-2, influenza virus, and flavivirus, protective immunity against chronic and emerging infectious disease can be elicited.https://www.frontiersin.org/articles/10.3389/fmicb.2023.1249718/fullTLRhepatitis virusHIVSARS-CoV-2influenza virus |
| spellingShingle | Mohammad Enamul Hoque Kayesh Michinori Kohara Kyoko Tsukiyama-Kohara TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview Frontiers in Microbiology TLR hepatitis virus HIV SARS-CoV-2 influenza virus |
| title | TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview |
| title_full | TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview |
| title_fullStr | TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview |
| title_full_unstemmed | TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview |
| title_short | TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview |
| title_sort | tlr agonists as vaccine adjuvants in the prevention of viral infections an overview |
| topic | TLR hepatitis virus HIV SARS-CoV-2 influenza virus |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1249718/full |
| work_keys_str_mv | AT mohammadenamulhoquekayesh tlragonistsasvaccineadjuvantsinthepreventionofviralinfectionsanoverview AT michinorikohara tlragonistsasvaccineadjuvantsinthepreventionofviralinfectionsanoverview AT kyokotsukiyamakohara tlragonistsasvaccineadjuvantsinthepreventionofviralinfectionsanoverview |